We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Article |

Disseminated Infection With Pneumocystis carinii Related to Administration of Pentamidine Aerosol

Stephen De Roux, MD; Volkan Adsay, MD; Harry L. Ioachim, MD
Arch Intern Med. 1991;151(8):1672. doi:10.1001/archinte.1991.00400080152037.
Text Size: A A A
Published online


To the Editor. —  A controlled clinical trial including 408 patients at 12 treatment centers was initiated in 1987 to assess the efficacy of aerosolized pentamidine for the prophylaxis of Pneumocystis carinii pneumonia.1 This study is of great importance, because in patients with acquired immunodeficiency syndrome (AIDS), P carinii continues to be the most common pathogenic agent with an incidence of 60% at presentation, causing severe life-threatening infections. The results of the prophylaxis trial recently published in the New England Journal of Medicine show that aerosolized pentamidine administered to patients infected with human immunodeficiency virus was beneficial in preventing P carinii pneumonia in proportion to dose and schedule of administration.1 While pneumonia is by far the most common manifestation of the P carinii infection in AIDS, sporadic cases of extrapulmonary or disseminated pneumocystosis, in addition to the pulmonary localization, have been reported.2-6 Several of them occurred in


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.